Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aegleio

- PMLiVE

Takeda to pay $2.4bn to settle Actos cancer suits

Will be one of the largest drug safety settlements in US history

- PMLiVE

Relief as study finds no cardiovascular risk with Januvia

FDA continues to investigate safety of numerous diabetes therapies

- PMLiVE

Sanofi wins European approval for Lantus follow-up Toujeo

Long-acting insulin is a key part of the company's growth plans

- PMLiVE

Saxenda debuts in US with $1,000-a-month price tag

It is the first market for Novo Nordisk’s obesity therapy

- PMLiVE

Pharma growing its use of social media – report

New data also highlights who leads the way in integrated social media marketing

- PMLiVE

Creston acquires How Splendid

Agency looks to bolster its digital offering with new buy

Making a difference with mobile health

Sanofi talks to PME about its latest mHealth initiative and tackling the diabetes epidemic

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

Novo Nordisk opens insulin facility in Russia

It will focus on new modern insulin formulation and filling

- PMLiVE

Going the distance

Sanofi’s Pascale Witz on driving through change

- PMLiVE

FDA starts review of Novo’s refiled diabetes pair

Tresiba and Ryzodeg were rejected in 2013

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links